Adma Biologics reported $49.19M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Adma Biologics USD 49.19M 7.26M Sep/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
BioCryst Pharmaceuticals USD -4.51M 12.2M Dec/2024
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Novavax USD -134.02M 49.55M Sep/2024
Omeros USD -48.15M 7.25M Sep/2023
Takeda JPY 257.49B 568.56B Dec/2025